Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy
Status:
Unknown status
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
Cyclosporin decreases proteinuria and improve renal function in patients with idiopathic
membranous nephropathy, but has a risk of side effects such as nephrotoxicity. The
investigators plan to the study to evaluate whether mycophenolate mofetil (MMF) could be a
reasonable alternative with fewer side effect.
Phase:
Phase 3
Details
Lead Sponsor:
Kyungpook National University Kyungpook National University Hospital